The company is currently one of the main bases for the production of domestic anti-drug resistant antibiotics and fluoroquinolone antibiotics. It is anti-drug resistant antibiotics, fluoroquinolone antibiotics, antimalarials, glycosidase inhibitors, diabetes drugs, immunosuppressive drugs, etc. It has certain advantages in
R&D, production and market development, and has strong international competitiveness.
The company attaches great importance to original research and technological innovation with independent intellectual property rights. It has established two technical platforms for industrial green chemistry and microencapsulation of active ingredients in the field of vitamin products, and has established distinctive
The company's pharmaceutical industry research institute has seven professional research institutes, nearly 200 scientific researchers engaged in new drugs, new product research and development, process and equipment technology innovation, etc. The company invests more than 100 million yuan in new product research and development every year.
The Shanghai Laiyi Biopharmaceutical Research and Development Center, which is controlled by the company and co-constructed with China Pharmaceutical University and Shanghai Jiaotong University, covers research areas: new drug screening, activity research, new technology development, generic drug development, and process optimization of enterprise products. Export certification technical support, etc.